1. Treatment of psoriasis in end-stage renal disease patients is associated with decreased mortality: A retrospective cohort study.
- Author
-
Schwade MJ, Tien L, Waller JL, Davis LS, Baer SL, Mohammed A, Young L, Kheda MF, and Bollag WB
- Subjects
- Adrenal Cortex Hormones administration & dosage, Aged, Cohort Studies, Databases, Factual trends, Dermatologic Agents administration & dosage, Female, Humans, Male, Middle Aged, Mortality trends, Retrospective Studies, Kidney Failure, Chronic drug therapy, Kidney Failure, Chronic mortality, Psoriasis drug therapy, Psoriasis mortality, Skin Diseases, Infectious drug therapy, Skin Diseases, Infectious mortality
- Abstract
Background: Psoriasis impairs the quality of life of approximately 7.5 million Americans and is associated with serious comorbidities. Because of chronic vascular access and epidermal dysfunction, end-stage renal disease (ESRD) patients with psoriasis may be at greater risk for infection, and psoriasis treatment could affect this risk., Methods: A retrospective cohort analysis was performed using the United States Renal Data System from 2004-2011 to investigate the association of psoriasis with infections common to ESRD patients, as well as the effect of psoriasis treatment on infection risk as well as mortality., Results: A total of 8,911 psoriasis patients were identified. Psoriasis was associated with a significantly increased risk for all queried infections, especially cellulitis (adjusted relative risk = 1.55), conjunctivitis (1.47), and onychomycosis (1.36). Psoriasis treatment (systemic, local, and light) was associated with a significantly decreased risk of some infections. Psoriasis treatment was also correlated with a significantly decreased risk of mortality, with systemic therapies (biologics and other immunosuppressants) showing the greatest reduction (adjusted hazard ratio = 0.55)., Conclusions: These results suggest that psoriasis-ESRD patients may have an increased risk of infection and treatment of psoriasis is associated with a reduced risk of some infections and improved survival., (Published by Elsevier Inc.)
- Published
- 2021
- Full Text
- View/download PDF